STOCK TITAN

Insulet Corporation (PODD) Stock Price, News & Analysis

PODD NASDAQ
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
17 252 sessions, November 14, 2025 to November 16, 2026
Largest daily move
-20.1% close of August 5, 2026
1-year change
-56.3% closing prices, November 14, 2025 to November 16, 2026
1-month change
+3% closing prices, October 16, 2026 to November 16, 2026

Company Description

Insulet Corporation (NASDAQ: PODD) is a medical device company in the surgical and medical instrument manufacturing industry, focused on simplifying life for people with diabetes and other conditions. Headquartered in Massachusetts, Insulet develops and commercializes its Omnipod product platform, a tubeless insulin pump technology that offers an alternative to traditional insulin delivery methods such as multiple daily injections.

The company’s core offering is the Omnipod Insulin Management System, which uses a small, wearable, tubeless disposable Pod that can provide up to three days of continuous subcutaneous insulin delivery. The Pod is designed so that users do not need to see or handle a needle during application, which can make insulin therapy less intimidating and more convenient. According to company disclosures, hundreds of thousands of insulin-dependent people with diabetes use Omnipod systems worldwide.

Omnipod 5 Automated Insulin Delivery System

Insulet’s flagship product is the Omnipod 5 Automated Insulin Delivery (AID) System. This system integrates with a continuous glucose monitor (CGM) to automate insulin delivery and manage blood sugar levels without multiple daily injections or routine fingersticks. In the U.S., Omnipod 5 can be controlled by a compatible personal smartphone or by a dedicated Omnipod 5 Controller, giving users flexibility in how they interact with the system.

The Omnipod 5 algorithm is designed to adjust insulin delivery based on CGM readings, aiming to keep glucose within a target range. Insulet has reported FDA 510(k) clearance for enhancements to the Omnipod 5 algorithm, including a lower 100 mg/dL Target Glucose setting and updates intended to help users remain in Automated Mode with fewer interruptions. These enhancements are described by the company as addressing highly requested features from both users and healthcare providers.

Tubeless, Wearable Design and User Experience

A defining feature of Insulet’s technology is the tubeless, wearable Pod. Unlike traditional insulin pumps that rely on tubing, the Omnipod Pod adheres directly to the body and delivers insulin continuously for up to three days before replacement. This form factor is emphasized by Insulet as central to user comfort, freedom of movement, and discretion. The company frequently highlights how this design can reduce the mental and practical burden of diabetes management.

Insulet also emphasizes human-centered and “liveable technology” principles in its product philosophy. In its communications, the company describes its goal as creating effortless, intelligent systems that fit naturally into daily life, reducing the cognitive load associated with chronic disease management. The Omnipod 5 system, with its automation and smartphone control options, is presented as an example of this approach.

Business Focus and Market Positioning

Insulet describes itself as the global leader in tubeless insulin pump technology through its Omnipod brand of products. The company focuses on automated insulin delivery for people with type 1 diabetes and insulin-intensive type 2 diabetes. It has communicated a strategic plan aimed at extending its role in what it characterizes as fast-growing and underpenetrated global markets for AID systems.

Insulet’s strategy, as outlined in its investor communications, includes accelerating innovation in its Omnipod platform, advancing clinical practice, expanding patient access, and generating demand through commercial execution. The company also refers to competitive advantages such as its unique Pod form factor, a pay-as-you-go pharmacy distribution model, automated manufacturing and supply chain capabilities, and brand recognition around Omnipod.

Non-Insulin Drug Delivery

Beyond insulin, Insulet reports that it leverages its Pod technology for non-insulin subcutaneous drug delivery across other therapeutic areas. The company states that it tailors its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs, using the same core Pod design principles. While specific non-insulin products are not detailed in the provided materials, this activity is described as an extension of the Omnipod platform into additional medical applications.

Financial Reporting and Growth Framework

As a publicly traded company on the NASDAQ, Insulet regularly reports financial results and outlooks. In its communications, the company uses non-GAAP financial measures such as constant currency revenue growth, adjusted operating margin, adjusted diluted earnings per share, adjusted EBITDA, and free cash flow to describe its performance and financial goals. These measures are presented as supplemental to GAAP metrics and are used internally by management for performance evaluation and planning.

At its 2025 Investor Day, Insulet outlined a long-range financial outlook and a growth strategy for the 2025–2028 period. The company described its total addressable market for automated insulin delivery as exceeding $30 billion and discussed plans to drive growth through innovation in Omnipod systems, expansion of access and reimbursement, and continued investment in manufacturing scale.

Innovation Pipeline and Connected Health

Insulet has publicly described a multi-year innovation roadmap for its Omnipod platform. This includes enhancements to Omnipod 5 and plans for next-generation systems that are intended to expand the capabilities of automated insulin delivery and unlock new patient segments. The company has referenced future systems designed for adaptability, comfort, ease of use, and more advanced algorithms that learn from users’ glucose patterns.

In its participation at technology events such as the Consumer Electronics Show (CES), Insulet has presented its concept of “liveable technology” for connected health. This concept focuses on calm, human-first design and automation that works in the background, surfacing insights only when needed. Omnipod 5 is highlighted as an example of this approach, integrating medical technology, consumer experience, and digital health.

Sustainability and Recycling Initiatives

Insulet has announced sustainability initiatives related to its Pod products. In the United States, the company expanded a Pod recycling program that allows customers to request recycling kits at no cost, return used Pods for decontamination, and have them processed by a company specializing in recycling electronics and medical products. Insulet states that this program is intended to reduce landfill waste and support circular solutions. The company also reports longstanding Pod takeback programs in several international markets.

Brand and Community Engagement

The Omnipod brand is central to Insulet’s identity. The company refers to its users as “Podders” and highlights the role of Omnipod in fostering a sense of community and empowerment among people living with diabetes. In collaboration with Pantone, Insulet introduced “Omnipod Mango,” a distinctive orange-yellow color associated with the brand and its community. This color is described as symbolizing the joy, individuality, and visibility of people who wear Omnipod devices.

Through events, user stories, and design choices, Insulet emphasizes the emotional and lifestyle aspects of diabetes management, positioning Omnipod as both a medical device and a visible expression of personal identity for many users.

Regulatory and Governance Disclosures

Insulet’s SEC filings provide additional insight into its operations and governance. The company files periodic reports and current reports on Form 8-K to disclose material events, such as financial results, executive appointments, board changes, and updates to compensation plans. For example, filings describe the appointment of new executive leadership, amendments to incentive plans, and the appointment of independent directors with extensive healthcare and financial experience.

These disclosures reflect Insulet’s obligations as a NASDAQ-listed issuer and provide investors with information about its leadership, compensation structures, and significant corporate events.

Company Origins and Mission

Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy easier to use for people with diabetes. This objective led to the development of the Omnipod system, which received U.S. Food and Drug Administration (FDA) approval in 2005. Since then, the company reports that approximately 500,000 insulin-dependent patients worldwide have used Omnipod systems.

Across its public communications, Insulet consistently describes its mission as transforming and simplifying life for people with diabetes. By focusing on a tubeless, wearable Pod platform, automation through Omnipod 5, and extensions into non-insulin drug delivery, the company positions itself at the intersection of medical devices, digital health, and patient-centered design.

Stock Performance

$145.29
-4.72%
-7.19
Last updated: November 16, 2026 at 16:00
-56.3%
Performance 1 year
$10.1B

Insulet Corporation (PODD) closed at $145.29 on November 16, 2026. Over the past 12 months, the price has lost 56.3%.

See what a $1,000 investment in PODD would be worth today

Average down calculator for PODD

PODD Metrics & Rankings

Price returns through November 16, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Insider Radar

Net Buyers
90-Day Summary
1,100
Shares Bought
0
Shares Sold
1
Transactions
Most Recent Transaction
McEvoy Ashley (President and CEO) bought 1,100 shares @ $147.47 on August 21, 2026

Insider buying activity at Insulet Corporation over the past 90 days may reflect management confidence in the company's direction. Institutional investors and analysts often monitor insider purchases as a potential bullish indicator for the stock.

Based on SEC Form 4 filings over the last 90 days.

Financial Highlights

Insulet Corporation generated $2.7B in revenue in FY2025, retaining a 71.6% gross margin, operating income reached $473.8M (17.5% operating margin), and net income was $247.1M, reflecting a 9.1% net profit margin. Diluted earnings per share stood at $3.48. The company generated $569.3M in operating cash flow. The current ratio was 2.81, measuring current assets divided by current liabilities.

$2.7B
Revenue (FY2025)
$247.1M
Net Income (FY2025)
$569.3M
Operating Cash Flow

Upcoming Events

NOV
18
November 18, 2026 Marketing

Jefferies presentation

Presentation at Jefferies Global Healthcare Conference in London; 10:30 a.m. GMT. Live webcast/replay at investors.insulet.com
H1
2027
H1 2027 Product

Greece launch

Planned commercial availability of Omnipod 5 in Greece in H1 2027.
H1
2027
H1 2027 Product

Croatia launch

Planned commercial availability of Omnipod 5 in Croatia in H1 2027.
YEAR
2027
2027 Regulatory

510(k) regulatory filing

Planned 510(k) submission to FDA for Omnipod FCL automated insulin system.
YEAR
2027
2027 Regulatory

510(k) filing

Insulet plans a 510(k) regulatory submission to FDA in 2027 for FCL AID system; timeline subject to FDA review.
YEAR
2028
2028 Product

Commercial launch

Planned commercial launch of Omnipod FCL automated insulin delivery system.
APR
01
April 1, 2033 Financial

Senior notes maturity

Insulet Corporation has 7 upcoming scheduled events. The next event, "Jefferies presentation", is scheduled for November 18, 2026 (in 2 days). 1 of them is a financing or capital event, such as a dividend or a debt maturity. Investors can track these dates to stay informed about potential catalysts that may affect the PODD stock price.

Short Interest History

Last 12 Months

Short interest in Insulet Corporation (PODD) currently stands at 5.3 million shares, down 5.4% from the previous reporting period, representing 7.8% of the float. Since November 2025, short interest has increased by 155.4%.

Days to Cover History

Last 12 Months

Days to cover for Insulet Corporation (PODD) currently stands at 4.3 days, up 36.2% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has increased by 84.8%. Across the settlements charted above, it has ranged from 1.5 to 4.3 days.

PODD Company Profile & Sector Positioning

Insulet Corporation (PODD) operates in the Medical Devices industry within the broader Healthcare sector and is listed on the NASDAQ.

Investors comparing PODD often look at related companies in the same sector, including Smith & Nephew plc (SNN), Penumbra, Inc. (PEN), Glaukos Corporation (GKOS), Zimmer Biomet Holdings, Inc. (ZBH), and STERIS plc (STE). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate PODD's relative position within its industry.

Frequently Asked Questions

The current stock price of Insulet Corporation (PODD) is $145.29 as of November 16, 2026.

The market cap of Insulet Corporation (PODD) is approximately $10.1B. Learn more about what market capitalization means .

The FY2025 revenue of Insulet Corporation (PODD) is $2.7B, from its most recent completed fiscal year.

The FY2025 net income of Insulet Corporation (PODD) is $247.1M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of Insulet Corporation (PODD) is $3.48 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of Insulet Corporation (PODD) is $569.3M for FY2025, its most recent completed fiscal year. Learn about cash flow.

The net profit margin of Insulet Corporation (PODD) is 9.1% for FY2025, its most recent completed fiscal year. Learn about profit margins.

The operating profit margin of Insulet Corporation (PODD) is 17.5% for FY2025, its most recent completed fiscal year. Learn about operating margins.

The gross profit margin of Insulet Corporation (PODD) is 71.6% for FY2025, its most recent completed fiscal year. Learn about gross margins.

The current ratio of Insulet Corporation (PODD), current assets divided by current liabilities, was 2.81 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The gross profit of Insulet Corporation (PODD) is $1.9B for FY2025, its most recent completed fiscal year.

The operating income of Insulet Corporation (PODD) is $473.8M for FY2025, its most recent completed fiscal year. Learn about operating income.

Insulet Corporation is a medical device company that develops and commercializes the Omnipod product platform, a tubeless insulin pump technology designed to simplify life for people with diabetes and other conditions. Its Omnipod Insulin Management System uses a small, wearable Pod to deliver continuous subcutaneous insulin as an alternative to traditional insulin delivery methods.

The Omnipod Insulin Management System is Insulet’s core product. It consists of a tubeless, disposable Pod that adheres to the body and can provide up to three days of continuous insulin delivery. The design allows users to receive insulin without handling a needle and is intended to replace multiple daily injections and other traditional insulin delivery methods.

Omnipod 5 is an Automated Insulin Delivery (AID) system that integrates with a continuous glucose monitor to automatically adjust insulin delivery. According to Insulet, Omnipod 5 manages blood sugar without multiple daily injections or routine fingersticks and can be controlled in the U.S. by a compatible personal smartphone or by the Omnipod 5 Controller.

Insulet has reported FDA 510(k) clearance for significant enhancements to the Omnipod 5 algorithm, including a lower 100 mg/dL Target Glucose option and updates intended to help users stay in Automated Mode with fewer interruptions. These changes are described as addressing highly requested features from users and healthcare providers and are aimed at improving customization and the overall user experience.

Insulet describes itself as the global leader in tubeless insulin pump technology through its Omnipod brand of products. The company focuses on automated insulin delivery for people with type 1 and insulin-intensive type 2 diabetes and emphasizes its unique tubeless Pod form factor and Omnipod platform as key differentiators.

Yes. Insulet states that it leverages the unique design of its Omnipod Pod by tailoring its technology platform for the delivery of non-insulin subcutaneous drugs in other therapeutic areas. This extends the use of its Pod-based delivery system beyond insulin, although specific non-insulin products are not detailed in the provided materials.

Insulet Corporation is headquartered in Massachusetts and its common stock trades on The NASDAQ Stock Market under the ticker symbol PODD. The company’s SEC filings identify it as a registrant with principal executive offices in Acton, Massachusetts.

In its communications, Insulet uses the term “liveable technology” to describe its vision for connected health systems that are effortless, intelligent, and fit naturally into daily life. This concept emphasizes human-first design and automation that reduces the mental burden of managing chronic conditions such as diabetes, with Omnipod 5 highlighted as an example.

Insulet has announced a U.S. Pod recycling program that allows customers to request recycling kits at no cost, return used Pods for decontamination, and have them processed by a recycling company that handles electronics and medical products. The company states that this program, along with Pod takeback programs in several international markets, is intended to divert Pods from landfills and support circular solutions.

Insulet refers to users of its Omnipod systems as “Podders.” The company highlights stories from Podders and emphasizes community, empowerment, and self-expression in its branding. Its collaboration with Pantone to create the Omnipod Mango color is presented as a visual symbol of the Podder community and Insulet’s commitment to improving life for people with diabetes.

Insulet’s SEC filings include current reports on Form 8-K that cover topics such as quarterly financial results, amendments to incentive plans, executive and board appointments, and other material corporate events. These filings provide investors with information on the company’s financial condition, governance, and significant changes in leadership or compensation arrangements.